Early Diagnosis of Alzheimer’s Disease: Moving Toward a Blood-Based Biomarkers Era

References

• Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577–1590. doi:10.1016/S0140-6736(20)32205-4
   PubMed Web of Science ®Google Scholar
• Palmqvist S, Insel PS, Stomrud E, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease. EMBO Mol Med. 2019;11(12):e11170. doi:10.15252/emmm.201911170
   PubMed Web of Science ®Google Scholar
• Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312–339. doi:10.1016/j.cell.2019.09.001
   PubMed Web of Science ®Google Scholar
• Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dementia. 2018;14(4):535–562. doi:10.1016/j.jalz.2018.02.018
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet. 2022;21(1):66–77. doi:10.1016/S1474-4422(21)00361-6
   Web of Science ®Google Scholar
• McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dementia. 2011;7(3):263–269. doi:10.1016/j.jalz.2011.03.005
   PubMed Web of Science ®Google Scholar
• Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet. 2021;20(6):484–496. doi:10.1016/S1474-4422(21)00066-1
   Web of Science ®Google Scholar
• Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dementia. 2022;2022:154.
   Google Scholar
• Hansson O, Zetterberg H, Vanmechelen E, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging. 2010;31(3):357–367. doi:10.1016/j.neurobiolaging.2008.03.027
   PubMed Web of Science ®Google Scholar
• Janelidze S, Stomrud E, Palmqvist S, et al. Plasma beta-amyloid in Alzheimer’s disease and vascular disease. Sci Rep. 2016;6:26801. doi:10.1038/srep26801
   PubMed Web of Science ®Google Scholar
• Verberk IMW, Slot RE, Verfaillie SCJ, et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol. 2018;84(5):648–658. doi:10.1002/ana.25334
   PubMed Web of Science ®Google Scholar
• Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature. 2018;554(7691):249–254. doi:10.1038/nature25456
   PubMed Web of Science ®Google Scholar
• Janelidze S, Teunissen CE, Zetterberg H, et al. Head-to-head comparison of 8 plasma amyloid-beta 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375–1382. doi:10.1001/jamaneurol.2021.3180
   Web of Science ®Google Scholar
• Karikari TK, Benedet AL, Ashton NJ, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s disease neuroimaging initiative. Mol Psychiatry. 2021;26(2):429–442. doi:10.1038/s41380-020-00923-z
   PubMed Web of Science ®Google Scholar
• Lin RR, Xue YY, Li XY, Chen YH, Tao QQ, Wu ZY. Optimal combinations of AT(N) biomarkers to determine longitudinal cognition in the Alzheimer’s disease. Front Aging Neurosci. 2021;13:718959. doi:10.3389/fnagi.2021.718959
   Web of Science ®Google Scholar
• Lantero Rodriguez J, Karikari TK, Suarez-Calvet M, et al. Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140(3):267–278. doi:10.1007/s00401-020-02195-x
   PubMed Web of Science ®Google Scholar
• Cousins KAQ, Shaw LM, Shellikeri S, et al. Elevated plasma phosphorylated tau 181 in amyotrophic lateral sclerosis. Ann Neurol. 2022;92(5):807–818. doi:10.1002/ana.26462
   Web of Science ®Google Scholar
• Janelidze S, Stomrud E, Smith R, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Nat Commun. 2020;11(1):1683. doi:10.1038/s41467-020-15436-0
   PubMed Web of Science ®Google Scholar
• Bayoumy S, Verberk IMW, den Dulk B, et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther. 2021;13(1):198. doi:10.1186/s13195-021-00939-9
   Web of Science ®Google Scholar
• Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772–781. doi:10.1001/jama.2020.12134
   PubMed Web of Science ®Google Scholar
• Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet. 2021;20(9):739–752. doi:10.1016/S1474-4422(21)00214-3
   Web of Science ®Google Scholar
• Abbasi J. Alzheimer blood test using tau biomarker is in development. JAMA. 2020;323(14):1336.
   Web of Science ®Google Scholar
• Shahim P, Zetterberg H, Simren J, et al. Association of plasma biomarker levels with their CSF concentration and the number and severity of concussions in professional athletes. Neurology. 2022;99(4):e347–e354. doi:10.1212/WNL.0000000000200615
   Web of Science ®Google Scholar
• Garcia-Moreno H, Prudencio M, Thomas-Black G, et al. Tau and neurofilament light-chain as fluid biomarkers in spinocerebellar ataxia type 3. Eur J Neurol. 2022;29(8):2439–2452. doi:10.1111/ene.15373
   PubMed Web of Science ®Google Scholar
• Li QF, Dong Y, Yang L, et al. Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3. Mol Neurodegener. 2019;14(1):39. doi:10.1186/s13024-019-0338-0
   Web of Science ®Google Scholar
• Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med. 2019;25(2):277–283. doi:10.1038/s41591-018-0304-3
   PubMed Web of Science ®Google Scholar
• Rathcke CN, Vestergaard H. YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8:61. doi:10.1186/1475-2840-8-61
   PubMed Web of Science ®Google Scholar
• Perez MF, Atuegwu NC, Mortensen EM, Oncken C. The inflammatory biomarker YKL-40 is elevated in the serum, but not the sputum, of E-cigarette users. Exp Lung Res. 2021;47(2):55–66. doi:10.1080/01902148.2020.1847216
   PubMed Web of Science ®Google Scholar
• Steiner J, Bogerts B, Schroeter ML, Bernstein HG. S100B protein in neurodegenerative disorders. Clin Chem Lab Med. 2011;49(3):409–424. doi:10.1515/CCLM.2011.083
   PubMed Web of Science ®Google Scholar
• Oeckl P, Halbgebauer S, Anderl-Straub S, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67(2):481–488. doi:10.3233/JAD-180325
   PubMed Web of Science ®Google Scholar
• Abu-Rumeileh S, Steinacker P, Polischi B, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimers Res Ther. 2019;12(1):2. doi:10.1186/s13195-019-0562-4
   Web of Science ®Google Scholar
• Chatterjee P, Pedrini S, Stoops E, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease. Transl Psychiatry. 2021;11(1):27. doi:10.1038/s41398-020-01137-1
   PubMed Web of Science ®Google Scholar
• Beyer L, Stocker H, Rujescu D, et al. Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer’s disease diagnosis within 17 years. Alzheimers Dementia. 2022. doi:10.1002/alz.12745
   Web of Science ®Google Scholar
• Benussi A, Ashton NJ, Karikari TK, et al. Serum Glial Fibrillary Acidic Protein (GFAP) is a marker of disease severity in frontotemporal lobar degeneration. J Alzheimers Dis. 2020;77(3):1129–1141.
   Web of Science ®Google Scholar
• Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer’s disease. Brain. 2021;144(11):3505–3516. doi:10.1093/brain/awab223
   PubMedGoogle Scholar
• Ferri E, Rossi PD, Geraci A, Ciccone S, Cesari M, Arosio B. The sTREM2 concentrations in the blood: a marker of neurodegeneration? Front Mol Biosci. 2020;7:627931. doi:10.3389/fmolb.2020.627931
   Web of Science ®Google Scholar
• Weber GE, Khrestian M, Tuason ED, et al. Peripheral sTREM2-related inflammatory activity alterations in early-stage Alzheimer’s disease. J Immunol. 2022;208(10):2283–2299. doi:10.4049/jimmunol.2100771
   Web of Science ®Google Scholar
• Liu D, Cao B, Zhao Y, et al. Soluble TREM2 changes during the clinical course of Alzheimer’s disease: a meta-analysis. Neurosci Lett. 2018;686:10–16. doi:10.1016/j.neulet.2018.08.038
   PubMed Web of Science ®Google Scholar
• Tsai HH, Chen YF, Yen RF, et al. Plasma soluble TREM2 is associated with white matter lesions independent of amyloid and tau. Brain. 2021;144(11):3371–3380. doi:10.1093/brain/awab332
   Google Scholar
• Kleinberger G, Yamanishi Y, Suarez-Calvet M, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6(243):243ra286. doi:10.1126/scitranslmed.3009093
   Web of Science ®Google Scholar
• Wilson EN, Swarovski MS, Linortner P, et al. Soluble TREM2 is elevated in Parkinson’s disease subgroups with increased CSF tau. Brain. 2020;143(3):932–943. doi:10.1093/brain/awaa021
   Google Scholar
• Lu Y, Zhao Y, Zhang Q, et al. Soluble TREM2 is associated with death and cardiovascular events after acute ischemic stroke: an observational study from CATIS. J Neuroinflammation. 2022;19(1):88. doi:10.1186/s12974-022-02440-y
   Web of Science ®Google Scholar
• Bader JM, Geyer PE, Muller JB, et al. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer’s disease. Mol Syst Biol. 2020;16(6):e9356. doi:10.15252/msb.20199356
   PubMed Web of Science ®Google Scholar